Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a ...

Shares of Bausch Health, Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO. The industry declined 0.6% during ...

In its latest warning letter, FDA raised concern that the company was still producing eye drops with amniotic fluid, even ...

Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness myths. On my spare time I enjoy ...

The global ophthalmic eye drop market is poised for steady growth over the next decade. The market, which was valued at USD ...

A study reveals laughter exercise is as effective as artificial tears for dry eye disease, improving symptoms and tear film ...

Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with ...

this is a good opportunity for the market to finally realize what we have in Bausch + Lomb. I would keep a close eye on the potential buyout rumors because that is the most obvious means to see an ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times ...